Volume | 6,305 |
|
|||||
News | - | ||||||
Day High | 5.37 | Low High |
|||||
Day Low | 5.0648 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.30 | 5.0648 | 5.37 | 5.17 | 5.37 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
123 | 6,305 | $ 5.13 | $ 32,330 | - | 2.78 - 8.8465 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:14:01 | 96 | $ 5.50 | USD |
Aprea Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
19.32M | 3.74M | - | 583k | -14.29M | -3.82 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aprea Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.81 | 5.88 | 5.0648 | 5.29 | 4,987 | -0.64 | -11.02% |
1 Month | 6.31 | 6.80 | 5.0648 | 6.14 | 8,964 | -1.14 | -18.07% |
3 Months | 5.04 | 8.8465 | 4.9401 | 6.64 | 35,198 | 0.13 | 2.58% |
6 Months | 3.81 | 8.8465 | 3.35 | 6.13 | 22,026 | 1.36 | 35.70% |
1 Year | 3.86 | 8.8465 | 2.78 | 4.69 | 26,030 | 1.31 | 33.94% |
3 Years | 92.80 | 156.00 | 2.78 | 80.01 | 621,170 | -87.63 | -94.43% |
5 Years | 309.20 | 1,062.20 | 2.78 | 118.31 | 562,629 | -304.03 | -98.33% |
Aprea Therapeutics Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |